FR0013280286

BioMerieux S.A.

BIM

valor: 1888685

isin: FR0013280286

Sector: Health Care

BioMerieux S.A.

Price:

EUR 105.20

BIM

valor:

1888685

isin:

FR0013280286

Sector:

Health Care

RIC

BIOX.PA

Bloomberg

BIM FP EQUITY

Asset Class

Stock

Country

France

Reference Currency

EUR

Trading Exchange

Euronext Paris

Trading Currency

EUR

Bid

104.20
26.02.2021
400.00

Ask

106.20
26.02.2021
400.00

Last

105.20
26.02.2021

Daily High

107.30

Change in %

-0.47 %

Change absolut

-0.94

Hist. volatility 30d

29.66 %

Hist. volatility 90d

46.76 %

Hist. volatility 180d

46.75 %

Overview Structured Products on BioMerieux S.A.

Leverage	Participation	Yield Enhancement	Capital Protection	Reference Entity
{{u.cnt20}}	{{u.cnt13}}	{{u.cnt12}}	{{u.cnt11}}	{{u.cnt14}}
Exchange Traded Funds (ETFs)				{{etfs}}
Leverage {{u.cnt20}} Participation {{u.cnt13}} Yield Enhancement {{u.cnt12}} Capital Protection {{u.cnt11}} Reference Entity {{u.cnt14}}
Exchange Traded Funds (ETFs) {{etfs}}

Details

RIC

BIOX.PA

Bloomberg

BIM FP EQUITY

Asset Class

Stock

Country

France

Reference Currency

EUR

Quotes

Trading Exchange

Euronext Paris

Trading Currency

EUR

Bid

104.20
26.02.2021
400.00

Ask

106.20
26.02.2021
400.00

Last

105.20
26.02.2021

Daily High

107.30

Change in %

-0.47 %

Change absolut

-0.94

Valuations

Hist. volatility 30d

29.66 %

Hist. volatility 90d

46.76 %

Hist. volatility 180d

46.75 %

Charts

Related Products

Overview Structured Products on BioMerieux S.A.

Leverage	Participation	Yield Enhancement	Capital Protection	Reference Entity
{{u.cnt20}}	{{u.cnt13}}	{{u.cnt12}}	{{u.cnt11}}	{{u.cnt14}}
Exchange Traded Funds (ETFs)				{{etfs}}
Leverage {{u.cnt20}} Participation {{u.cnt13}} Yield Enhancement {{u.cnt12}} Capital Protection {{u.cnt11}} Reference Entity {{u.cnt14}}
Exchange Traded Funds (ETFs) {{etfs}}

Posts

Trading Desk, 08/02/2021

«The Week»: Illumina befindet sich voll auf Zug

Trading Desk, 01/02/2021

«The Week»: Teladoc geht durch die Decke

Trading Desk, 25/01/2021

«The Week»: Wuxi Biologics mit riesigem Potential